CRISPR/Cas9-mediated disruption of the CBX5 gene in K-562 human chronic myelogenous leukemia cells yields a polyclonal knockout cell population engineered to ablate HP1?? protein expression. This polyclonal pool, derived from a heterogeneous mixture of edited alleles, provides a loss-of-function model without clonal isolation. The CBX5 knockout disrupts a central heterochromatin regulator, enabling studies of epigenetically silenced genomic regions and chromatin dynamics in a leukemia background.
The K-562 cell line was established from a female patient with chronic myelogenous leukemia in blast crisis and harbors the BCR-ABL1 fusion oncogene. This multipotent hematopoietic progenitor line exhibits characteristics of erythroid, myeloid, and megakaryocytic lineages and serves as a widely used model for leukemia biology, erythroid differentiation, and apoptosis. Its suspension-growth properties and responsiveness to differentiation inducers such as hemin and sodium butyrate make it experimentally tractable for genetic perturbation and phenotypic screening.
CBX5 encodes HP1??, a member of the heterochromatin protein 1 family, which specifically recognizes and binds histone H3 lysine 9 trimethylation (H3K9me3) deposited by SUV39H1/2 methyltransferases. HP1?? binding nucleates heterochromatin assembly, recruiting factors such as the lamin B receptor (LBR), chromatin assembly factor 1 (CAF-1), and DNA methyltransferases (DNMTs) to propagate silencing and chromatin compaction. HP1?? cooperates with CBX1 and CBX3 isoforms and interacts with transcriptional repressors like TIF1?? and SETDB1. Its function is regulated by Aurora B kinase-mediated phosphorylation and SUMOylation, which modulate its chromatin affinity. Downstream, HP1?? maintains silencing of repetitive elements and tumor suppressor loci such as CDKN1A, influencing cell cycle progression, senescence, and genomic stability.
In K-562 cells, CBX5 disruption abrogates HP1??-directed heterochromatin maintenance, potentially relieving repression at HP1?? target genes and repetitive sequences. This loss-of-function model is particularly relevant for dissecting epigenetic control of BCR-ABL1-driven leukemogenesis, as heterochromatin perturbations can alter differentiation propensities and drug sensitivity. K-562 cells undergo erythroid or megakaryocytic differentiation in response to specific signals, and HP1?? deficiency may shift lineage commitment or accelerate senescence-like phenotypes, providing a platform to study chromatinopathies and senescence-associated pathways in a CML context.
The CBX5 knockout K-562 polyclonal population is well-suited for chromatin immunoprecipitation coupled to quantitative PCR (ChIP-qPCR) assessing H3K9me3 redistribution, immunofluorescence microscopy of disrupted heterochromatin foci, and co-immunoprecipitation to examine SUV39H1 complex integrity. Researchers can pair these cells with western blotting for HP1?? loss, RT-qPCR for derepressed genes such as CDKN1A, and functional assays including senescence-associated ??-galactosidase activity, Annexin V apoptosis profiling, and MTT proliferation assays. Flow cytometric monitoring of CD235a expression allows evaluation of erythroid differentiation, while drug treatment studies enable exploration of epigenetic synergy with tyrosine kinase inhibitors or DNMT inhibitors. For further technical details and ordering information, please contact Ascent Research.
